KLK3 and neoplasm: Enza treatment slightly, but insignificantly, suppressed tumor PSA expression (p = 0.28), ARVib-7 treatment significantly suppressed PSA (p = 0.029) and the combination treatment further reduced PSA levels (p = 0.0053) (Fig. 6F).